109 related articles for article (PubMed ID: 10825443)
1. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo.
Lopes de Menezes DE; Pilarski LM; Belch AR; Allen TM
Biochim Biophys Acta; 2000 Jun; 1466(1-2):205-20. PubMed ID: 10825443
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
3. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
Sapra P; Moase EH; Ma J; Allen TM
Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
5. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes.
Sapra P; Allen TM
Clin Cancer Res; 2004 Apr; 10(7):2530-7. PubMed ID: 15073133
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
7. Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin.
Lundberg BB; Griffiths G; Hansen HJ
Int J Pharm; 2000 Sep; 205(1-2):101-8. PubMed ID: 11000546
[TBL] [Abstract][Full Text] [Related]
8. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.
Moase EH; Qi W; Ishida T; Gabos Z; Longenecker BM; Zimmermann GL; Ding L; Krantz M; Allen TM
Biochim Biophys Acta; 2001 Feb; 1510(1-2):43-55. PubMed ID: 11342146
[TBL] [Abstract][Full Text] [Related]
9. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP).
Atobe K; Ishida T; Ishida E; Hashimoto K; Kobayashi H; Yasuda J; Aoki T; Obata K; Kikuchi H; Akita H; Asai T; Harashima H; Oku N; Kiwada H
Biol Pharm Bull; 2007 May; 30(5):972-8. PubMed ID: 17473445
[TBL] [Abstract][Full Text] [Related]
10. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.
Brignole C; Marimpietri D; Gambini C; Allen TM; Ponzoni M; Pastorino F
Cancer Lett; 2003 Jul; 197(1-2):199-204. PubMed ID: 12880982
[TBL] [Abstract][Full Text] [Related]
11. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach.
Iden DL; Allen TM
Biochim Biophys Acta; 2001 Aug; 1513(2):207-16. PubMed ID: 11470092
[TBL] [Abstract][Full Text] [Related]
13. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.
Sapra P; Allen TM
Cancer Res; 2002 Dec; 62(24):7190-4. PubMed ID: 12499256
[TBL] [Abstract][Full Text] [Related]
14. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells.
Cheng WW; Das D; Suresh M; Allen TM
Biochim Biophys Acta; 2007 Jan; 1768(1):21-9. PubMed ID: 17046711
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells.
Ishida T; Kirchmeier MJ; Moase EH; Zalipsky S; Allen TM
Biochim Biophys Acta; 2001 Dec; 1515(2):144-58. PubMed ID: 11718670
[TBL] [Abstract][Full Text] [Related]
16. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract][Full Text] [Related]
17. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo.
Vingerhoeds MH; Steerenberg PA; Hendriks JJ; Dekker LC; Van Hoesel QG; Crommelin DJ; Storm G
Br J Cancer; 1996 Oct; 74(7):1023-9. PubMed ID: 8855969
[TBL] [Abstract][Full Text] [Related]
18. Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody.
Lundberg BB; Griffiths G; Hansen HJ
Drug Deliv; 2007 Mar; 14(3):171-5. PubMed ID: 17454037
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytotoxic study of immunoliposomal doxorubicin targeted to human CD34(+) leukemic cells.
Carrion C; de Madariaga MA; Domingo JC
Life Sci; 2004 Jun; 75(3):313-28. PubMed ID: 15135652
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
